Jpmorgan Chase & CO Lyra Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 56,277 shares of LYRA stock, worth $417,575. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,277

Previous 156,442 64.03%

Holding current value

$417,575

Previous $32,000 78.13%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$0.13 - $0.22 $13,021 - $22,036	-100,165 Reduced 64.03%	56,277 $7,000
Q4 2024 Feb 12, 2025	BUY	$0.17 - $0.28 $16,435 - $27,070	96,681 Added 161.78%	156,442 $32,000
Q3 2024 Dec 26, 2024	BUY	$0.24 - $0.34 $9,384 - $13,294	39,102 Added 189.27%	59,761 $15,000
Q3 2024 Nov 08, 2024	BUY	$0.24 - $0.34 $9,384 - $13,294	39,102 Added 189.27%	59,761 $15,000
Q2 2024 Dec 26, 2024	SELL	$0.26 - $6.25 $10,166 - $244,387	-39,102 Reduced 65.43%	20,659 $5,000
Q2 2024 Aug 12, 2024	SELL	$0.26 - $6.25 $23,073 - $554,662	-88,746 Reduced 81.12%	20,659 $5,000
Q1 2024 Dec 26, 2024	BUY	$4.55 - $6.53 $225,880 - $324,175	49,644 Added 83.07%	109,405 $680,000
Q1 2024 May 10, 2024	BUY	$4.55 - $6.53 $346,869 - $497,814	76,235 Added 229.83%	109,405 $680,000
Q4 2023 Dec 26, 2024	SELL	$2.82 - $5.24 $74,986 - $139,336	-26,591 Reduced 44.5%	33,170 $173,000
Q4 2023 Feb 12, 2024	BUY	$2.82 - $5.24 $93,443 - $173,632	33,136 Added 97458.82%	33,170 $173,000
Q2 2022 Aug 11, 2022	SELL	$4.12 - $7.51 $31,827 - $58,014	-7,725 Reduced 99.56%	34 $0
Q1 2022 May 11, 2022	BUY	$3.5 - $5.36 $24,185 - $37,037	6,910 Added 813.9%	7,759 $31,000
Q4 2021 Feb 10, 2022	BUY	$4.22 - $9.41 $3,439 - $7,669	815 Added 2397.06%	849 $4,000
Q3 2021 Nov 12, 2021	BUY	$6.06 - $9.43 $206 - $320	34 New	34 $0

Others Institutions Holding LYRA

# of Institutions

Shares Held

2.9M

Call Options Held

Put Options Held

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $236M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Lyra Therapeutics, Inc. Transaction History